Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) hide within the worldwide human population. While dormant in the vast majority of those infected, these active herpesviruses can develop into several forms of cancer.

14 Feb 2013

Burkitt lymphoma risk after transplantation highlighted

Solid organ transplant recipients have a significant risk for developing Burkitt lymphoma (BL), US researchers have found.

12 Feb 2013

HDL cholesterol key to fighting lymphoma

High-density lipoprotein cholesterol could provide a novel treatment target for patients with lymphoma, US scientists believe.

25 Jan 2013

EBV reactivation can increase risk of heart disease

A new study could provide the link that scientists have been looking for to confirm that reactivation of a latent herpes virus is a cause of some heart problems.

23 Jan 2013

New study: Loneliness can harm overall health

New research links loneliness to a number of dysfunctional immune responses, suggesting that being lonely has the potential to harm overall health.

20 Jan 2013

Study finds important links between Pf malaria and endemic Burkitt Lymphoma

New research, presented this morning at the 54th Annual Meeting of the American Society of Hematology (ASH), has identified important associations between Plasmodium falciparum (Pf) malaria and endemic Burkitt Lymphoma (eBL) that may help researchers identify young children who are more susceptible to eBL.

12 Dec 2012

Potential diagnostic method to identify subset of patients with chronic fatigue syndrome

For the first time, researchers have landed on a potential diagnostic method to identify at least a subset of patients with chronic fatigue syndrome (CFS), a complex disorder with no known definitive cause or cure.

15 Nov 2012

Comparing animal and human cancer is of mutual benefit

A diagnosis of cancer once spelled the end for our animal companions but the launch today of a specialty cancer clinic, led by one of Australia’s leading veterinary oncologists at the University of Sydney, offers new hope.

14 Oct 2012

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.

5 Sep 2012

The Wistar Institute, MSKCC partner to publish first annotated atlas of Epstein-Barr virus genome

Researchers from The Wistar Institute and Memorial Sloan-Kettering Cancer Center (MSKCC) have teamed to publish the first annotated atlas of the Epstein-Barr virus genome, creating the most comprehensive study of how the viral genome interacts with its human host during a latent infection. Epstein-Barr virus (EBV), which is thought to be responsible for one percent of all human cancers, establishes a latent infection in nearly 100 percent of infected adult humans.

24 Aug 2012

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.

7 Aug 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

RNP granules exit the nucleus via new budding mechanism akin to herpes-type viruses

New evidence published in Cell by Vivian Budnik, PhD, Melissa J. Moore, PhD, and colleagues at the University of Massachusetts Medical School, reveals a novel budding mechanism, similar to the process used by some viruses, capable of exporting large ribonucleoprotein particles from the nucleus to the cytoplasm.

11 May 2012

Abbott receives CE Marking for PLEX-ID instrument and assays

Abbott announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.

31 Mar 2012

EBV can infect and may also contribute to lymphomas in man's best friend

More than 90 percent of humans have antibodies to the Epstein Barr virus. Best known for causing mononucleosis, or "the kissing disease," the virus has also been implicated in more serious conditions, including Hodgkin's, non-Hodgkin's and Burkitt's lymphomas. Yet little is known about exactly how EBV triggers these diseases.

13 Mar 2012

Study addresses how human body controls gamma-herpesviruses

New research from the Trudeau Institute addresses how the human body controls gamma-herpesviruses, a class of viruses thought to cause a variety of cancers. The study, carried out in the laboratory of Dr. Marcia Blackman, awaits publication in The Journal of Immunology.

13 Mar 2012

Study reveals immune mechanism for surveillance over EBV infection

Some 90 percent of people are exposed to the Epstein Barr virus (EBV) at some point in their life. Even though it is quickly cleared from the body, the virus can linger silently for years in small numbers of infected B cells.

18 Feb 2012

Blood cell therapy works for nasopharyngeal cancer: Study

Scientists from the Queensland Institute of Medical Research have made a breakthrough in the treatment of throat cancer. The researchers have developed a therapy that uses a patient's blood to grow special white blood cells that recognize and fight infected cancer cells. The results of this study have been published in the journal Cancer Research.

2 Feb 2012

New NIST clinical SRM can help in accurate CMV detection and treatment

A new clinical Standard Reference Material (SRM) from the National Institute of Standards and Technology (NIST) will help health care professionals more accurately diagnose and treat cytomegalovirus (CMV), a common pathogen that is particularly dangerous for infants and persons with weakened immune systems.

12 Jan 2012

Study shows how Epstein-Barr virus triggers MS

A new study from researchers at Queen Mary, University of London shows how a particular virus tricks the immune system into triggering inflammation and nerve cell damage in the brain, which is known to cause MS.

6 Jan 2012